Event JSON
{
"id": "e3cb0723583b0c5b929fce1ac7f34a41767f468c71167114cdcfee63be0894bf",
"pubkey": "af947eb1ac2a94a86b48cbbda851396b8bcaa9aa59c9322e7c3da8264e0e9878",
"created_at": 1734450753,
"kind": 1,
"tags": [
[
"r",
"https://en.globes.co.il/en/article-1001497039#utm_source=RSS"
],
[
"subject",
"Teva jumps sharply on bowel disease drug results"
],
[
"published_at",
"1734457517"
],
[
"image",
"https://res.cloudinary.com/globes/image/upload/t_800X392/v1658892717/direct/shutterstock_1795020259_afq1af.jpg"
],
[
"p",
"af947eb1ac2a94a86b48cbbda851396b8bcaa9aa59c9322e7c3da8264e0e9878",
"wss://relay-testnet.k8s.layer3.news"
],
[
"imeta",
"url https://res.cloudinary.com/globes/image/upload/t_800X392/v1658892717/direct/shutterstock_1795020259_afq1af.jpg"
],
[
"t",
"unkown:perspective"
],
[
"summary",
"Teva and Sanofi announced that the trial met its primary endpoints in ulcerative colitis and Crohn's disease, the most common forms of inflammatory bowel disease. The companies plan to initiate Phase 3 development for treating inflammatory bowel diseases, which affect an estimated 10 million people worldwide. The treatment, Dukavitug, showed a significant improvement in clinical remission and endoscopic response compared to placebo."
]
],
"content": "nostr:nprofile1qy3hwumn8ghj7un9d3shjtt5v4ehgmn9wshxkwrn9ekxz7t9wgejumn9waesqg90j3ltrtp2jj5xkjxthk59zwtt3092n2jeeyezulpa4qnyur5c0qh5y6qj\nhttps://res.cloudinary.com/globes/image/upload/t_800X392/v1658892717/direct/shutterstock_1795020259_afq1af.jpg\nTeva reported that the trial for Dukaviyug, which it is developing with Sanofi, met its endpoints in ulcerative colitis and Crohn's disease, the most common forms of inflammatory bowel disease.\nhttps://en.globes.co.il/en/article-1001497039#utm_source=RSS",
"sig": "a098bdfbcef4b7827489fa5b256978fcde9fa4624fb802d0fa578c71ca345367359712742b2161de70e6eacdb6d5a9c18aafe54c70d5e1853ea8f80e3425d550"
}
